Top

Published in:

01-12-2009

Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study

Authors: K. Elmasry, A. J. Davies, D. G. Evans, M. N. Seif, K. Reynolds

Published in: Familial Cancer | Issue 4/2009

Abstract

Lynch syndrome is an autosomal dominant syndrome accounting for 2–5% of all colorectal cancer. In addition, women with Lynch syndrome have a substantially increased risk of developing endometrial cancer particularly pre-menopausally when symptom detection is more difficult. Current recommendations are that screening for endometrial cancer be offered to women identified to be at risk. The aim of the study was to assess the relative patient acceptability of the available screening modalities. A survey of the perception of the associated pain or discomfort associated with different screening modalities was conducted. Transvaginal ultrasonography was associated with less discomfort than hysteroscopy or Pipelle biopsy, and would be the single test of choice for the majority. There was no significant difference between the pain scores for hysteroscopy and Pipelle biopsy. Issues relating to test acceptability specific to this population are described. Patient acceptability of screening modalities should form an integral part of studies assessing the effectiveness of endometrial screening in the Lynch syndrome population.

Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368(6468):258–261CrossRefPubMed

Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456CrossRefPubMed

Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218CrossRefPubMed

Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677–685CrossRefPubMed

Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT (1994) The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96(6):516–520CrossRefPubMed

Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T et al (1994) The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14(4B):1675–1678PubMed

Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105–110CrossRefPubMed

Banno K, Susumu N, Yanokura M, Hirao T, Iwata T, Hirasawa A et al (2004) Association of HNPCC and endometrial cancers. Int J Clin Oncol 9(4):262–269CrossRefPubMed

Lu HK, Broaddus RR (2005) Gynecologic cancers in Lynch syndrome/HNPCC. Fam Cancer 4(3):249–254CrossRefPubMed

10.

Brown GJ, St John DJ, Macrae FA, Aittomaki K (2001) Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 80(3):346–349CrossRefPubMed

11.

Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834CrossRefPubMed

12.

Pylvanainen K, Kairaluoma M, Mecklin JP (2006) Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer 5(2):175–178CrossRefPubMed

13.

Collins V, Meiser B, Gaff C, St John DJ, Halliday J (2005) Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer 104(2):273–281CrossRefPubMed

14.

Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. Jama 277(11):915–919CrossRefPubMed

15.

Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al (1997) A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89(23):1758–1762CrossRefPubMed

16.

American-Cancer-Society. Can endometrial cancer be found early?

17.

Downes E, al-Azzawi F (1993) The predictive value of outpatient hysteroscopy in a menopause clinic. Br J Obstet Gynaecol 100(12):1148–1149PubMed

18.

Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K et al (1995) Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study. Am J Obstet Gynecol 172(5):1488–1494CrossRefPubMed

19.

Taipale P, Tarjanne H, Heinonen UM (1994) The diagnostic value of transvaginal sonography in the diagnosis of endometrial malignancy in women with peri- and postmenopausal bleeding. Acta Obstet Gynecol Scand 73(10):819–823CrossRefPubMed

20.

Tahir MM, Bigrigg MA, Browning JJ, Brookes ST, Smith PA (1999) A randomised controlled trial comparing transvaginal ultrasound, outpatient hysteroscopy and endometrial biopsy with inpatient hysteroscopy and curettage. Br J Obstet Gynaecol 106(12):1259–1264PubMed

21.

Goldstein SR, Zeltser I, Horan CK, Snyder JR, Schwartz LB (1997) Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 177(1):102–108CrossRefPubMed

22.

Wilson JMG, Junger G (1968) Principles and practice of screening for disease. WHO, Geneva

23.

Vasen HF, Mecklin JP, Khan PM, Lynch HT (1994) The International Collaborative Group on HNPCC. Anticancer Res 14(4B):1661–1664PubMed

24.

Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF et al (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94(6):1708–1712CrossRefPubMed

25.

Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG (2003) Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91(1):74–80CrossRefPubMed

26.

Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP (2000) The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89(8):1765–1772CrossRefPubMed

27.

Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK (2002) Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. Bjog 109(3):313–321PubMed

28.

Wood NJ, Munot S, Sheridan E, Duffy SR (2008) Does a “one-stop” gynecology screening clinic for women in hereditary nonpolyposis colorectal cancer families have an impact on their psychological morbidity and perception of health? Int J Gynecol Cancer 18(2):279–284CrossRefPubMed

29.

Stewart-Brown S, Farmer A (1997) Screening could seriously damage your health. BMJ 314:533PubMed

30.

Marteau TM, Kidd J, Cook R (1988) Screening for Down’s syndrome. BMJ 297(6661):1469CrossRefPubMed

31.

Cockburn J, Staples M, Hurley SF (1994) Psychological consequences of screening mammography. J Med Screen 1:7–12PubMed

32.

Williams GL, Clarke P, Vellacott KD (2006) Anxieties should not be forgotten when screening relatives of colorectal cancer patients by colonoscopy. Colorectal Dis 8:781–784CrossRefPubMed

33.

Katz DA, Jarrard DF, McHorney CA (2007) Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 69:215–220CrossRefPubMed

34.

Lau WC, Lo WK, Tam WH, Yuen PM (1999) Paracervical anaesthesia in outpatient hysteroscopy: a randomised double-blind placebo-controlled trial. Br J Obstet Gynaecol 106(4):356–359PubMed

35.

Jacobs I (2005) Screening for familial ovarian cancer: the need for well-designed prospective studies. J Clin Oncol 23(24):5443–5445CrossRefPubMed

36.

Bell R, Petticrew M, Luengo S, Sheldon TA (1998) Screening for ovarian cancer: a systematic review. Health Technol Assess 2(2):1–84 i–iv

37.

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A et al (2008) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. doi:10.1136/jmg.2008.058248

Title: Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study
Authors: K. Elmasry
A. J. Davies
D. G. Evans
M. N. Seif
K. Reynolds
Publication date: 01-12-2009
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-009-9259-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

FAP-associated desmoid invasiveness correlates with in vitro resistance to doxorubicin

Molecular study of CEPBA in familial hematological malignancies

Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome

Impact of 226C>T MSH2 gene mutation on cancer phenotypes in two HNPCC-associated highly-consanguineous families from Kuwait: emphasis on premarital genetic testing

Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome

Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer